Drug Profile
Research programme: anti-HER2 monoclonal antibodies - InNexus Biotechnology
Alternative Names: DXL 702Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InNexus Biotechnology
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in Canada (Parenteral)
- 21 Feb 2008 Preclinical trials in Breast cancer in Canada (Parenteral)